Regression analysis incorporating all serum samples measured on both analyzers revealed a proportional difference of 21% for the Immulite analyzer (n ϭ 135; r ϭ 0.97, Spearman rank correlation). Samples measured in EDTA or cooled EDTA plasma on the Immulite showed differences of 15% and 19%, respectively (n ϭ 135; r ϭ 0.97 and 0.96, Spearman rank correlation), compared with the Immulite 2000.
Finally, we tested the in vitro stability of PTH by measuring PTH before and after storage of serum and plasma for 48 h at 4°C. Serum PTH decreased from a median concentration of 2.6 pmol/L to 2.4 pmol/L within 48 h (P ϭ 0.0003, Wilcoxon test). PTH in EDTA plasma increased marginally, from 3.8 pmol/L to 4.1 pmol/L (P ϭ 0.008, Wilcoxon test), and PTH in ice-cold EDTA plasma remained constant at ϳ3.2 pmol/L (P ϭ 0.52, Wilcoxon test). The quality-control data indicated that there was no obvious drift. Although for serum and EDTA plasma the changes in PTH concentrations with time are statistically significant, the clinical relevance of the changes is questionable.
The results presented here confirm previous reports describing higher apparent PTH concentrations in EDTA plasma than in serum (1, 2 ) and changes in PTH concentrations with time (1) (2) (3) (4) (5) (6) . In agreement with what has been published for the DPC PTH assay (1 ), we found a slight increase in PTH concentration in EDTA plasma with time. The decrease in serum PTH concentrations was much less profound after 2 days (this study) than after 3 days (1 ) after venipuncture. This may be attributable to the fact that in the study of Glendenning et al.
(1 ) the samples were stored at room temperature, whereas we stored them, similar to patient material, at 4°C. The observation that PTH does not decrease in EDTA plasma at room temperature may be attributable to chelation by EDTA of cations essential to (metallo)protease activity.
In conclusion, reference intervals for PTH are dependent on sample type, and reports on the stability of PTH in serum and plasma are inconsistent. Therefore, within one laboratory, PTH should be determined in one type of sample only and as soon as possible after venipuncture. Excess EDTA in an underfilled tube can inhibit signal production in methods that use alkaline phosphatase; for such methods, serum should be the material of choice. Laboratories measuring PTH on both the Immulite and Immulite 2000 analyzers should make sure that the analyzers give similar results for patient material.
DPC Nederland (Breda, The Netherlands) kindly provided the PTH reagents used in this study. To the Editor: Gene expression profiling by microarray technology has demonstrated the possibilities of biological separation, prognostication, and prediction (1, 2 ) . In this study we demonstrate that the addition of proteinase K to the extraction procedure improves the yield of RNA from primary breast tumors, making the majority of samples eligible for array analysis by Qiagen RNeasy Minikit. In addition, we investigated whether the addition of proteinase K has any influence on the gene expression profile.
Volkher
The Qiagen RNeasy Mini protocol was used as described by the manufacturer (3, 4 ) for extraction of total RNA from 209 frozen primary breast tumors from women who had undergone surgery for breast cancer at Karolinska Hospital. The study was approved by an ethics committee at the hospital. Biopsies from the same tumors were extracted either with or without proteinase K treatment as follows. Each sample (maximum of 40 mg) was cut into smaller pieces and homogenized for 30 -40 s in 400 L of RLT lysis buffer containing mercaptoethanol with use of a polytron PT1200 homogenizer (Kinematica AG). For the proteinase KϪ sample, one volume (400 L) of 700 g/L ethanol was added to the homogenate, with mixing during the addition, after which the sample was applied to a RNeasy mini spin column. For the proteinase Kϩ sample, 785 L of doubly distilled water plus 13.5 L of proteinase K (20 g/L; Qiagen GmbH) was added to the homogenate, which was then mixed and incubated for 10 min at 55°C.
Clinical Chemistry
The proteinase Kϩ sample was then centrifuged at 12 000g for 2 min, and 600 L of absolute ethanol was added to the supernatant, with mixing during the addition. The sample was then applied to a RNeasy mini spin column. From this point, the same procedure was followed for both the proteinase KϪ and proteinase Kϩ samples. The column was washed once with 350 L of RW1 buffer followed by on-column treatment with 80 L of DNase solution (10 L of DNase ϩ 70 L of RDD buffer from the Qiagen RNase-free DNase reagent set) for 15 min, according to the Qiagen recommendations. The column was then washed once with 350 L of RW1 and twice with 500 L of RPE buffer. Finally, the RNA was eluted with 50 L of RNase-free water. We assessed the quality of the RNA by measuring the 28S:18S ribosomal RNA ratio with the Agilent 2100 Bioanalyzer (Agilent Technologies).
Proteinase K treatment increased the mean yield of RNA more than 10-fold, from 1.54 g (range, 0 -64.3 g) to 20.3 g (range, 0 -125.6 g). The proteinase K treatment increased the number of samples that could be used for microarray analyses from 10 of 209 to 152 of 209 samples (P Ͻ0.0001, Fisher exact two-tailed test) with 2 g as the minimum amount of RNA per tumor required for the microarray studies.
To determine whether the addition of proteinase K has an effect on the gene expression profile, we performed microarray analyses according to the Affymetrix protocol, using Affymetrix HG-U133 (45 000 probe sets) chips because Affymetrix array results have shown high reproducibility (5 ). In two cases (biopsies 19 and 216), we performed gene expression analyses on two adjacent pieces from the same tumor, either including or excluding proteinase K in the RNA extraction procedure. The pairwise correlation coefficients for tumors 19 and 216 were 0.94 and 0.95, respectively, based on signal intensities of the probe sets, indicating that proteinase K treatment does not change the expression profile, whereas it increases the yield of RNA by making the tumor cells more accessible for extraction.
In summary, proteinase K treatment dramatically improves the yield of RNA without causing any significant changes in the expression profile when included in the Qiagen RNeasy protocol and markedly increases the amount of RNA purified from primary breast tumors by this method.
